Preclinical and clinical studies indicate that A3AR agonists meet this requirement; A3AR expression is increased in multiple tumors and A3AR agonists inhibit the growth of cancer cells in vitro and reduce tumor growth in vivo [15]. This evidence concerns the gene ADORA3 and cancer.